EM-5854
id:
em-5854-287-1399462
title:
EM-5854
text:
EM-5854 is a steroidal antiandrogen which was under development by Endoceutics, Inc. for the treatment of prostate cancer. It was first described in a patent in 2008, and was further characterized in 2012. EM-5854 reached phase I/II clinical trials for the treatment of prostate cancer but development was discontinued in March 2019. The drug acts as a potent and selective competitive antagonist of the androgen receptor (AR). Unlike other steroidal antiandrogens like cyproterone acetate, but simil
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/EM-5854
date created:
date modified:
2022-03-05T21:03:16Z
main entity:
{"identifier":"Q55610321","url":"https://www.wikidata.org/entity/Q55610321"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/8/8e/EM-5854.svg","width":512,"height":425}
fields total:
13
integrity:
15